Can seniors handle colon cancer chemo? new study aims to find out

NCT ID NCT02978612

Completed Disease control Sponsor: Oslo University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at how well patients aged 75 and older tolerate chemotherapy after surgery for stage III colon cancer. Researchers measured changes in daily living activities and used geriatric assessments and gene tests to predict outcomes. The goal is to better identify which older patients can benefit from chemotherapy without major loss of function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Capecitabine (Xeloda) chemotherapy
What this could lead to: If successful, this could help doctors decide which elderly patients can safely receive chemotherapy after colon cancer surgery without major loss of independence.
What could go wrong: This is a small Phase 2 study, so results may not apply to all patients. Chemotherapy can cause side effects like fatigue, nausea, and increased infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon carcinoma colonic neoplasm colorectal neoplasm malignant colon neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLON CANCER

Contacts and locations

Locations

Oslo University Hospital

Oslo, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.